{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T16:24:06Z","timestamp":1794846246032,"version":"4.9.1"},"reference-count":140,"publisher":"Oxford University Press (OUP)","issue":"Supplement_5","license":[{"start":{"date-parts":[[2020,12,6]],"date-time":"2020-12-06T00:00:00Z","timestamp":1607212800000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lupus nephritis (LN) is a frequent and severe manifestation of SLE. Along the decades, the epidemiology of LN and its clinical presentation have been changing. However, even though retrospective cohort studies report a decreased mortality rate and an improvement in the disease prognosis, the percentage of patients progressing into end stage renal disease (ESRD) keeps steady despite the improvements in therapeutic strategies. Current in-use medications have been available for decades now, yet over the years, regimens for optimizing their efficacy and minimizing toxicity have been developed. Therapeutic research is now moving towards the direction of precision medicine and several new drugs, targeting selectively different pathogenetic pathways, are currently under evaluation with promising results. In this review, we address the main changes and persistent unmet needs in LN management throughout the past decades, with a focus on prognosis and upcoming treatments.<\/jats:p>","DOI":"10.1093\/rheumatology\/keaa381","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T07:38:58Z","timestamp":1591947538000},"page":"v39-v51","source":"Crossref","is-referenced-by-count":217,"title":["Lupus nephritis: clinical presentations and outcomes in the 21st century"],"prefix":"10.1093","volume":"59","author":[{"given":"Michela","family":"Gasparotto","sequence":"first","affiliation":[{"name":"Rheumatology Unit, Department of Medicine, University of Padua"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariele","family":"Gatto","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine, University of Padua"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Binda","sequence":"additional","affiliation":[{"name":"Nephrology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0548-4983","authenticated-orcid":false,"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine, University of Padua"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Moroni","sequence":"additional","affiliation":[{"name":"Nephrology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,5]]},"reference":[{"key":"2020120517370472000_keaa381-B1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrrheum.2015.159","article-title":"What is damaging the kidney in lupus nephritis?","volume":"12","author":"Davidson","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"2020120517370472000_keaa381-B2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.kint.2016.03.042","article-title":"Insight into the epidemiology and management of lupus nephritis from the US rheumatologist\u2019s perspective","volume":"90","author":"Hoover","year":"2016","journal-title":"Kideny Int"},{"key":"2020120517370472000_keaa381-B3","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/rheumatology\/kev311","article-title":"The frequency and outcome of lupus nephritis: results from an international inception cohort study","volume":"55","author":"Hanly","year":"2016","journal-title":"Rheumatology"},{"key":"2020120517370472000_keaa381-B4","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.amjmed.2005.11.034","article-title":"Long-term prognosis and causes of death in systemic lupus erythematosus","volume":"119","author":"Doria","year":"2006","journal-title":"Am J Med"},{"key":"2020120517370472000_keaa381-B5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1191\/0961203302lu158oa","article-title":"Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis","volume":"11","author":"Bastian","year":"2002","journal-title":"Lupus"},{"key":"2020120517370472000_keaa381-B6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaut.2016.06.006","article-title":"Lupus nephritis: when and how often to biopsy and what does it mean?","volume":"74","author":"Moroni","year":"2016","journal-title":"J Autoimmun"},{"key":"2020120517370472000_keaa381-B7","doi-asserted-by":"crossref","first-page":"c105","DOI":"10.1159\/000081551","article-title":"Renal outcome and predictors of clinical renal involvement in patients with silent lupus nephritis","volume":"98","author":"Wada","year":"2004","journal-title":"Nephron Clin Pract"},{"key":"2020120517370472000_keaa381-B8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1191\/0961203305lu2055oa","article-title":"Clinical presentation and monitoring of lupus nephritis","volume":"14","author":"Balow","year":"2005","journal-title":"Lupus"},{"key":"2020120517370472000_keaa381-B9","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1136\/annrheumdis-2017-212732","article-title":"Changing patterns in clinical\u2013histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis","volume":"77","author":"Moroni","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2020120517370472000_keaa381-B10","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2020120517370472000_keaa381-B11","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2020120517370472000_keaa381-B12","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nrneph.2009.130","article-title":"Glomerular disease: lupus nephritis treatment: are we beyond cyclophosphamide?","volume":"5","author":"Rovin","year":"2009","journal-title":"Nat Rev Nephrol"},{"key":"2020120517370472000_keaa381-B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00041552-200501000-00002","article-title":"The role of kidney biopsy in the management of lupus nephritis","volume":"14","author":"Mittal","year":"2005","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2020120517370472000_keaa381-B14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1191\/0961203303lu259oa","article-title":"Silent nephritis in systemic lupus erythematosus","volume":"12","author":"Zabaleta-Lanz","year":"2003","journal-title":"Lupus"},{"key":"2020120517370472000_keaa381-B15","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2020120517370472000_keaa381-B16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.5114\/reum.2016.60214","article-title":"Do we still need renal biopsy in lupus nephritis?","volume":"2","author":"Ha\u0142adyj","year":"2016","journal-title":"Reumatologia"},{"key":"2020120517370472000_keaa381-B17","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 update of the Joint European League Against Rheumatism and European Renal Association\u2013European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2020120517370472000_keaa381-B18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000354390","article-title":"Differential diagnosis of glomerular disease: a systematic and inclusive approach","volume":"38","author":"Hebert","year":"2013","journal-title":"Am J Nephrol"},{"key":"2020120517370472000_keaa381-B19","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1093\/ndt\/gfl159","article-title":"Kidney biopsy in lupus nephritis: look before you leap","volume":"21","author":"Bihl","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"2020120517370472000_keaa381-B20","doi-asserted-by":"crossref","first-page":"138","DOI":"10.2215\/CJN.03400412","article-title":"Lupus nephritis: is the kidney biopsy currently necessary in the management of lupus nephritis?","volume":"8","author":"Giannico","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020120517370472000_keaa381-B21","first-page":"332","article-title":"Renal biopsy in lupus patients with low levels of proteinuria","volume":"34","author":"Christopher-Stine","year":"2007","journal-title":"J Rheumatol"},{"key":"2020120517370472000_keaa381-B22","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","article-title":"Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis","volume":"71","author":"Bertsias","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2020120517370472000_keaa381-B23","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ajkd.2003.08.001","article-title":"Approach to renal biopsy","volume":"42","author":"Fogo","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"2020120517370472000_keaa381-B24","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S0272-6386(99)70082-X","article-title":"Clinical and prognostic value of serial renal biopsies in lupus nephritis","volume":"34","author":"Moroni","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"2020120517370472000_keaa381-B25","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.21037\/atm.2018.09.47","article-title":"Re-biopsy in lupus nephritis","volume":"6","author":"Anders","year":"2018","journal-title":"Ann Transl Med"},{"key":"2020120517370472000_keaa381-B26","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.kint.2018.05.021","article-title":"A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy","volume":"94","author":"De Rosa","year":"2018","journal-title":"Kidney Int"},{"key":"2020120517370472000_keaa381-B27","doi-asserted-by":"crossref","first-page":"e000018","DOI":"10.1136\/lupus-2014-000018","article-title":"Role of early repeated renal biopsies in lupus nephritis","volume":"1","author":"Zickert","year":"2014","journal-title":"Lupus Sci Med"},{"key":"2020120517370472000_keaa381-B28","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/ndt\/gfv296","article-title":"Histologic versus clinical remission in proliferative lupus nephritis","volume":"32","author":"Malvar","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2020120517370472000_keaa381-B29","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.kint.2016.05.017","article-title":"A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis","volume":"90","author":"Anders","year":"2016","journal-title":"Kidney Int"},{"key":"2020120517370472000_keaa381-B30","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1523-1755.2004.00443.x","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"65","author":"Weening","year":"2004","journal-title":"Kidney Int"},{"key":"2020120517370472000_keaa381-B31","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","article-title":"Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions and modified National Institutes of Health activity and chronicity indices","volume":"93","author":"Bajema","year":"2018","journal-title":"Kidney Int"},{"key":"2020120517370472000_keaa381-B32","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s00296-009-0905-8","article-title":"Lupus nephritis among 624 cases of systemic lupus erythematosus in Riyadh, Saudi Arabia","volume":"29","author":"Al Arfaj","year":"2009","journal-title":"Rheumatol Int"},{"key":"2020120517370472000_keaa381-B33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3109\/03009740903456300","article-title":"Minimal mesangial lupus nephritis: a systematic review","volume":"39","author":"Mok","year":"2010","journal-title":"Scand J Rheumatol"},{"key":"2020120517370472000_keaa381-B34","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1093\/ndt\/gfp091","article-title":"Changing prevalence of glomerular diseases in Korean adults: a review of 20 years of experience","volume":"24","author":"Chang","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"2020120517370472000_keaa381-B35","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1177\/0961203315593166","article-title":"Long-term renal outcomes in a cohort of 1814 Chinese patients with biopsy-proven lupus nephritis","volume":"24","author":"Yang","year":"2015","journal-title":"Lupus"},{"key":"2020120517370472000_keaa381-B36","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/00005792-199905000-00002","article-title":"Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center","volume":"78","author":"Huong","year":"1999","journal-title":"Medicine"},{"key":"2020120517370472000_keaa381-B37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5606\/ArchRheumatol.2017.6127","article-title":"A systematic review and meta-analysis of prevalence of biopsy-proven lupus nephritis","volume":"33","author":"Wang","year":"2018","journal-title":"Arch Rheumatol"},{"key":"2020120517370472000_keaa381-B38","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1191\/0961203303lu446oa","article-title":"Mesangial lupus nephritis in Chinese is associated with a high rate of transformation to higher grade nephritis","volume":"12","author":"Tam","year":"2003","journal-title":"Lupus"},{"key":"2020120517370472000_keaa381-B39","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1007\/s00296-011-1986-8","article-title":"ISN\/RPS 2003 class II mesangial proliferative lupus nephritis: a comparison between cases that progressed to class III or IV and cases that did not","volume":"32","author":"Lee","year":"2012","journal-title":"Rheumatol Int"},{"key":"2020120517370472000_keaa381-B40","first-page":"299","article-title":"Long-term Outcome of Lupus Nephritis Class II in argentine patients: an open retrospective analysis","volume":"22","author":"Collado","year":"2016","journal-title":"J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis"},{"key":"2020120517370472000_keaa381-B41","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.semarthrit.2011.08.002","article-title":"Membranous nephropathy in systemic lupus erythematosus: long-term outcome and prognostic factors of 103 patients","volume":"41","author":"Moroni","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"2020120517370472000_keaa381-B42","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1191\/0961203305lu2062oa","article-title":"Membranous lupus nephritis","volume":"14","author":"Austin","year":"2005","journal-title":"Lupus"},{"key":"2020120517370472000_keaa381-B43","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1681\/ASN.2011060558","article-title":"Segmental and global subclasses of class IV lupus nephritis have similar renal outcomes","volume":"23","author":"Haring","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2020120517370472000_keaa381-B44","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.ackd.2019.06.002","article-title":"Classification of Lupus Nephritis;","volume":"26","author":"Stokes","year":"2019","journal-title":"Time for a Change? Adv Chronic Kidney Dis"},{"key":"2020120517370472000_keaa381-B45","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s40620-017-0463-1","article-title":"Lupus podocytopathy: a distinct entity of lupus nephritis","volume":"31","author":"Chen","year":"2018","journal-title":"J Nephrol"},{"key":"2020120517370472000_keaa381-B46","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2215\/CJN.01880216","article-title":"Lupus podocytopathy: a distinct entity","volume":"11","author":"Bomback","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020120517370472000_keaa381-B47","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2215\/CJN.06720615","article-title":"Clinical\u2013morphological features and outcomes of lupus podocytopathy","volume":"11","author":"Hu","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020120517370472000_keaa381-B48","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/0961203313517152","article-title":"Podocyte injury in pure membranous and proliferative lupus nephritis: distinct underlying mechanisms of proteinuria?","volume":"23","author":"Rezende","year":"2014","journal-title":"Lupus"},{"key":"2020120517370472000_keaa381-B49","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nrneph.2017.85","article-title":"Redefining lupus nephritis: clinical implications of pathophysiologic subtypes","volume":"13","author":"Yu","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"2020120517370472000_keaa381-B50","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1056\/NEJM198412133112402","article-title":"Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis","volume":"311","author":"Felson","year":"1984","journal-title":"N Engl J Med"},{"key":"2020120517370472000_keaa381-B51","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJM198603063141004","article-title":"Therapy of lupus nephritis","volume":"314","author":"Austin","year":"1986","journal-title":"N Engl J Med"},{"key":"2020120517370472000_keaa381-B52","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis","volume":"353","author":"Ginzler","year":"2005","journal-title":"N Engl J Med"},{"key":"2020120517370472000_keaa381-B53","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis","volume":"20","author":"Appel","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2020120517370472000_keaa381-B54","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2215\/CJN.03640412","article-title":"Lupus nephritis: maintenance therapy for lupus nephritis\u2014do we now have a plan?","volume":"8","author":"Lenz","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020120517370472000_keaa381-B55","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/ard.2008.102533","article-title":"The 10-year follow-up data of the Euro Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2020120517370472000_keaa381-B56","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2020120517370472000_keaa381-B57","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2147\/DDDT.S189156","article-title":"Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis","volume":"13","author":"Zhou","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"2020120517370472000_keaa381-B58","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/M14-1030","article-title":"Multitarget therapy for induction treatment of lupus nephritis: a randomized trial","volume":"162","author":"Liu","year":"2015","journal-title":"Ann Intern Med"},{"key":"2020120517370472000_keaa381-B59","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1681\/ASN.2017030263","article-title":"Multitarget therapy for maintenance treatment of lupus nephritis","volume":"28","author":"Zhang","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2020120517370472000_keaa381-B60","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1177\/0961203312442259","article-title":"Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial","volume":"21","author":"Chen","year":"2012","journal-title":"Lupus"},{"key":"2020120517370472000_keaa381-B61","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/ndt\/gfn565","article-title":"Cyclosporine (CsA) in lupus nephritis: assessing the evidence","volume":"24","author":"Moroni","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2020120517370472000_keaa381-B62","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2147\/DDDT.S195113","article-title":"Clinical efficacy and safety of rituximab in lupus nephritis","volume":"13","author":"Zhong","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"2020120517370472000_keaa381-B63","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5152\/eurjrheum.2018.17096","article-title":"Outcomes of rituximab therapy in refractory lupus: a meta-analysis","volume":"5","author":"Alshaiki","year":"2018","journal-title":"Eur J Rheumatol"},{"key":"2020120517370472000_keaa381-B64","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2020120517370472000_keaa381-B65","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2020120517370472000_keaa381-B66","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1136\/annrheumdis-2012-202844","article-title":"Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids","volume":"72","author":"Condon","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2020120517370472000_keaa381-B67","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/rheumatology\/ket462","article-title":"Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study","volume":"53","author":"Moroni","year":"2014","journal-title":"Rheumatology"},{"key":"2020120517370472000_keaa381-B68","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/nrrheum.2016.191","article-title":"Extent and patterns of off-label use of rituximab for SLE","volume":"12","author":"Sanz","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"2020120517370472000_keaa381-B69","first-page":"499","article-title":"Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry","volume":"33","author":"Iaccarino","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2020120517370472000_keaa381-B70","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/rheumatology\/ker337","article-title":"Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen","volume":"51","author":"Ezeonyeji","year":"2012","journal-title":"Rheumatology"},{"key":"2020120517370472000_keaa381-B71","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.autrev.2017.11.003","article-title":"Can we withdraw immunosuppressants in patients with lupus nephritis in remission? An expert debate","volume":"17","author":"Moroni","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2020120517370472000_keaa381-B72","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.autrev.2017.11.002","article-title":"Can we manage lupus nephritis without chronic corticosteroids administration?","volume":"17","author":"Lightstone","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2020120517370472000_keaa381-B73","doi-asserted-by":"crossref","first-page":"32087","DOI":"10.1038\/srep32087","article-title":"Calcineurin inhibitors cyclosporin A and tacrolimus protect against podocyte injury induced by puromycin aminonucleoside in rodent models","volume":"6","author":"Shen","year":"2016","journal-title":"Sci Rep"},{"key":"2020120517370472000_keaa381-B74","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nm.1857","article-title":"The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A","volume":"14","author":"Faul","year":"2008","journal-title":"Nat Med"},{"key":"2020120517370472000_keaa381-B75","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/ndt\/gfv102","article-title":"Lupus nephritis management guidelines compared","volume":"31","author":"Wilhelmus","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2020120517370472000_keaa381-B76","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/art.24538","article-title":"Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort","volume":"61","author":"Pons-Estel","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2020120517370472000_keaa381-B77","first-page":"1604","article-title":"Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome?","volume":"33","author":"Cunha","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2020120517370472000_keaa381-B78","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1177\/0961203307086503","article-title":"Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival","volume":"17","author":"Siso","year":"2008","journal-title":"Lupus"},{"key":"2020120517370472000_keaa381-B79","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1002\/art.22159","article-title":"Hydroxychloroquine in lupus pregnancy","volume":"54","author":"Clowse","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2020120517370472000_keaa381-B80","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.semnephrol.2017.05.006","article-title":"Lupus nephritis and pregnancy: concerns and management","volume":"37","author":"Lightstone","year":"2017","journal-title":"Semin Nephrol"},{"key":"2020120517370472000_keaa381-B81","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nrneph.2012.220","article-title":"Diagnosis and treatment of lupus nephritis flares\u2014an update","volume":"8","author":"Sprangers","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"2020120517370472000_keaa381-B82","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1038\/ki.1996.528","article-title":"\u201cNephritic flares\u201d are predictors of bad long-term renal outcome in lupus nephritis","volume":"50","author":"Moroni","year":"1996","journal-title":"Kidney Int"},{"key":"2020120517370472000_keaa381-B83","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/0961203308100481","article-title":"European consensus statement on the terminology used in the management of lupus glomerulonephritis","volume":"18","author":"Gordon","year":"2009","journal-title":"Lupus"},{"key":"2020120517370472000_keaa381-B84","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3899\/jrheum.161554","article-title":"Renal remission status and longterm renal survival in patients with lupus nephritis: a retrospective cohort analysis","volume":"45","author":"Davidson","year":"2018","journal-title":"J Rheumatol"},{"key":"2020120517370472000_keaa381-B85","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2215\/CJN.03280807","article-title":"Value of a complete or partial remission in severe lupus nephritis","volume":"3","author":"Chen","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020120517370472000_keaa381-B86","article-title":"Lack of EULAR\/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis [published online ahead of print, 2020 Jun 5].\u00a0Ann Rheum Dis","author":"Moroni","year":"2020","journal-title":"annrheumdis-2020-216965"},{"key":"2020120517370472000_keaa381-B87","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1002\/art.20666","article-title":"Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term follow-up of patients in the Euro-Lupus Nephritis Trial","volume":"50","author":"Houssiau","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2020120517370472000_keaa381-B88","doi-asserted-by":"crossref","first-page":"e000123","DOI":"10.1136\/lupus-2015-000123","article-title":"A proteinuria cut-off level of 0.7 g\/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial","volume":"2","author":"Tamirou","year":"2015","journal-title":"Lupus Sci Med"},{"key":"2020120517370472000_keaa381-B89","doi-asserted-by":"crossref","first-page":"5312960","DOI":"10.1155\/2017\/5312960","article-title":"Predictors of good long-term renal outcomes in lupus nephritis: results from a single lupus cohort","volume":"2017","author":"Fung","year":"2017","journal-title":"Biomed Res Int"},{"key":"2020120517370472000_keaa381-B90","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/art.40724","article-title":"Establishing surrogate kidney end points for lupus nephritis clinical trials: development and validation of a novel approach to predict future kidney outcomes","volume":"71","author":"Mackay","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2020120517370472000_keaa381-B91","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.semarthrit.2011.11.002","article-title":"Global trend of survival and damage of systemic lupus erythematosus: meta-analysis and meta-regression of observational studies from the 1950s to 2000s","volume":"41","author":"Mak","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"2020120517370472000_keaa381-B92","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1681\/ASN.V102413","article-title":"Lupus nephritis","volume":"10","author":"Cameron","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"2020120517370472000_keaa381-B93","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1093\/rheumatology\/ker101","article-title":"Assessment of a lupus nephritis cohort over a 30-year period","volume":"50","author":"Croca","year":"2011","journal-title":"Rheumatology"},{"key":"2020120517370472000_keaa381-B94","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3899\/jrheum.080625","article-title":"Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996-2004","volume":"36","author":"Ward","year":"2009","journal-title":"J Rheumatol"},{"key":"2020120517370472000_keaa381-B95","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/art.39594","article-title":"Risk of end-stage renal disease in patients with lupus nephritis, 1971\u20132015: a systematic review and Bayesian meta-analysis","volume":"68","author":"Tektonidou","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2020120517370472000_keaa381-B96","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1177\/0961203319847275","article-title":"Assessing the relative impact of lupus nephritis on mortality in a population-based systemic lupus erythematosus cohort","volume":"28","author":"Reppe Moe","year":"2019","journal-title":"Lupus"},{"key":"2020120517370472000_keaa381-B97","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/acr.20683","article-title":"Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality","volume":"64","author":"Jakes","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2020120517370472000_keaa381-B98","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1681\/ASN.2006090992","article-title":"Severe lupus nephritis: racial differences in presentation and outcome","volume":"18","author":"Korbet","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2020120517370472000_keaa381-B99","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1191\/0961203305lu2238oa","article-title":"Factors associated with poor outcomes in patients with lupus nephritis","volume":"14","author":"Contreras","year":"2005","journal-title":"Lupus"},{"key":"2020120517370472000_keaa381-B100","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1038\/sj.ki.5000243","article-title":"Outcomes in African Americans and Hispanics with lupus nephritis","volume":"69","author":"Contreras","year":"2006","journal-title":"Kidney Int"},{"key":"2020120517370472000_keaa381-B101","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2215\/CJN.05780616","article-title":"Update on lupus nephritis","volume":"12","author":"Almaani","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020120517370472000_keaa381-B102","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1093\/ndt\/gfg345","article-title":"Prognosis in proliferative lupus nephritis: the role of socio-economic status and race\/ethnicity","volume":"18","author":"Barr","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"2020120517370472000_keaa381-B103","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1177\/0961203311404912","article-title":"Age- and gender-related long-term renal outcome in patients with lupus nephritis","volume":"20","author":"Hsu","year":"2011","journal-title":"Lupus"},{"key":"2020120517370472000_keaa381-B104","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00296-009-1151-9","article-title":"Male gender results in more severe lupus nephritis","volume":"30","author":"De Carvalho","year":"2010","journal-title":"Rheumatol Int"},{"key":"2020120517370472000_keaa381-B105","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/096120339500400206","article-title":"Prognostic determinants in lupus nephritis: a long-term clinicopathologic study","volume":"4","author":"Donadio","year":"1995","journal-title":"Lupus"},{"key":"2020120517370472000_keaa381-B106","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1093\/ndt\/gfm245","article-title":"The long-term outcome of 93 patients with proliferative lupus nephritis","volume":"22","author":"Moroni","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"2020120517370472000_keaa381-B107","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1681\/ASN.2006040377","article-title":"How does proteinuria cause progressive renal damage?","volume":"17","author":"Abbate","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2020120517370472000_keaa381-B108","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/ki.1994.70","article-title":"Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data","volume":"45","author":"Austin","year":"1994","journal-title":"Kidney Int"},{"key":"2020120517370472000_keaa381-B109","first-page":"1620","article-title":"High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients","volume":"10","author":"HA","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"2020120517370472000_keaa381-B110","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.semarthrit.2019.06.002","article-title":"Clinical characteristics and renal prognosis associated with interstitial fibrosis and tubular atrophy (IFTA) and vascular injury in lupus nephritis biopsies","volume":"49","author":"Leatherwood","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2020120517370472000_keaa381-B111","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/acr.20441","article-title":"Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring","volume":"63","author":"Hsieh","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2020120517370472000_keaa381-B112","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1191\/0961203305lu2057oa","article-title":"Prognostic factors in lupus nephritis","volume":"14","author":"Mok","year":"2005","journal-title":"Lupus"},{"key":"2020120517370472000_keaa381-B113","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41584-020-0401-9","article-title":"Protecting the kidney in systemic lupus erythematosus: from diagnosis to therapy","volume":"16","author":"Maria","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2020120517370472000_keaa381-B114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2016.02.003","article-title":"Clinical and pathologic considerations of the qualitative and quantitative aspects of lupus nephritogenic autoantibodies: a comprehensive review","volume":"69","author":"Gatto","year":"2016","journal-title":"J Autoimmun"},{"key":"2020120517370472000_keaa381-B115","first-page":"208","article-title":"Immunization with pentraxin 3 (PTX3) leads to anti-PTX3 antibody production and delayed lupus-like nephritis in NZB\/NZW F1 mice","volume":"74","author":"Gatto","year":"2016","journal-title":"Compr Perspect Syst Lupus Erythematosus"},{"key":"2020120517370472000_keaa381-B116","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41584-018-0133-2","article-title":"New therapeutic strategies in systemic lupus erythematosus management","volume":"15","author":"Gatto","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"2020120517370472000_keaa381-B117","first-page":"94","article-title":"Success and failure of biological treatment in systemic lupus erythematosus: a critical analysis","volume":"74","author":"Gatto","year":"2016","journal-title":"Compr Perspect Syst Lupus Erythematosus"},{"key":"2020120517370472000_keaa381-B118"},{"key":"2020120517370472000_keaa381-B119"},{"key":"2020120517370472000_keaa381-B120"},{"key":"2020120517370472000_keaa381-B121"},{"key":"2020120517370472000_keaa381-B122"},{"key":"2020120517370472000_keaa381-B123"},{"key":"2020120517370472000_keaa381-B124"},{"key":"2020120517370472000_keaa381-B125"},{"key":"2020120517370472000_keaa381-B126"},{"key":"2020120517370472000_keaa381-B127"},{"key":"2020120517370472000_keaa381-B128","article-title":"Speed of remission with the use of voclosporin, MMF and low dose steroids: results of a global lupus nephritis study [abstract]","volume":"68","author":"Dooley","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2020120517370472000_keaa381-B129","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/acr.22971","article-title":"Effects of belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus","volume":"69","author":"Iaccarino","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2020120517370472000_keaa381-B130","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.autrev.2017.01.010","article-title":"Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: a systematic review","volume":"16","author":"Sciascia","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2020120517370472000_keaa381-B131","article-title":"Phase 2 trial of induction therapy with anti-CD20 (rituximab) followed by maintenance therapy with anti-BAFF (Belimumab) in patients with active lupus nephritis [abstract]","volume":"70","author":"Dall\u2019Era","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2020120517370472000_keaa381-B132","first-page":"643","article-title":"Successful sequential therapy with rituximab and belimumab in patients with active systemic lupus erythematosus: a case series","volume":"36","author":"Gualtierotti","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2020120517370472000_keaa381-B133","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41584-019-0235-5","article-title":"New therapies for systemic lupus erythematosus\u2014past imperfect, future tense","volume":"15","author":"Murphy","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"2020120517370472000_keaa381-B134"},{"key":"2020120517370472000_keaa381-B135","doi-asserted-by":"crossref","first-page":"1051.2","DOI":"10.1136\/annrheumdis-2016-eular.2397","article-title":"AB0423 Nobility, A Phase 2 Trial To Assess The Safety and Efficacy of Obinutuzumab, A Novel Type 2 Anti-CD20 Monoclonal Antibody (MAB), in Patients (PTS) with ISN\/RPS Class III or IV Lupus Nephritis (LN)","volume":"75","author":"Schindler","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2020120517370472000_keaa381-B136","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"2020120517370472000_keaa381-B137","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"2020120517370472000_keaa381-B138","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1177\/0961203310389100","article-title":"IL-17-producing T cells in lupus nephritis","volume":"20","author":"Apostolidis","year":"2011","journal-title":"Lupus"},{"key":"2020120517370472000_keaa381-B139","doi-asserted-by":"crossref","first-page":"8761","DOI":"10.4049\/jimmunol.181.12.8761","article-title":"Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys","volume":"181","author":"Crisp\u00edn","year":"2008","journal-title":"J Immunol"},{"key":"2020120517370472000_keaa381-B140","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.immuni.2012.08.014","article-title":"Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis","volume":"37","author":"Pisitkun","year":"2012","journal-title":"Immunity"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/Supplement_5\/v39\/34729964\/keaa381.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/Supplement_5\/v39\/34729964\/keaa381.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T20:57:04Z","timestamp":1666904224000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/59\/Supplement_5\/v39\/6024733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":140,"journal-issue":{"issue":"Supplement_5","published-online":{"date-parts":[[2020,12,5]]},"published-print":{"date-parts":[[2020,12,5]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa381","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,12]]}}}